3-AP and Cytarabine in Treating Patients With Hematologic Cancer
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy such as cytarabine use different ways to stop cancer
cells from dividing so they stop growing or die. 3-AP may stop the growth of cancer cells by
blocking the enzymes necessary for cancer cell growth and may help cytarabine kill more
cancer cells by making them more sensitive to the drug.
PURPOSE: Phase I trial to study the effectiveness of combining cytarabine with 3-AP in
treating patients who have relapsed or refractory hematologic cancer.